1658 results about "Inflammatory factors" patented technology

The present invention provides cystine derivatives, which may be in a free form, a salt form, a solvate form. The cystine derivatives of the present invention may be used to suppress activation of inflammatory factors. Accordingly, the present invention provides: compositions containing the cystine derivatives; a method for suppressing the activation of inflammatory factors by administering the composition; a method for preventing, ameliorating and / or therapeutically treating diseases, skin injuries or disorders involved in the activation of inflammatory factors by administering the composition; a method for preventing, delaying, ameliorating and / or therapeutically treating skin change via aging or aesthetically unfavorable skin change as induced or promoted by inflammatory factors by administering the composition; and pharmaceutical agents containing the cystine derivatives.

The invention discloses an application of anemoside B4 used as an immunomodulator to drugs for treating acute inflammations. The anti-inflammatory effect of the anemoside B4 is directly produced through inhibition of lymphocyte activation and inflammatory factor secretion. The application of the anemoside B4 used as the immunomodulator to the drugs for treating acute inflammations is disclosed for the first time, and the anemoside B4 belongs to a purely natural preparation, is safe, reliable and free of side effects and has potential development value for the drugs for treating acute inflammations.

The invention belongs to the field of allogenic mesenchymal stem cells, and particularly relates to a preparation method of allogenic mesenchymal stem cells by CRISPR (clustered regularly interspaced short palindromic repeats) technique editing and IGF (insulin-like growth factor) optimization and application of the allogenic mesenchymal stem cells in treating myocardial infarction. The preparation method comprises the following steps: carrying out separation by density gradient centrifugation to obtain allogenic single karyocytes, and carrying out adherent culture to obtain mesenchymal stem cells; designing a mesenchymal stem cell surface antigen B2M-gRNA and an inflammatory factor TNF-alpha-gRNA; establishing recombinant slow virus particles, and transfecting the mesenchymal stem cells; optimizing the mesenchymal stem cells by using IGF-1; and preparing drugs for treating myocardial infarctions by using the modified and optimized mesenchymal stem cells. The CRISPR / Cas9 technique is utilized to remove the antigens capable of causing immunological rejection and the inflammatory factors capable of causing inflammatory reaction on the mesenchymal stem cell surface, and the IGF-1 is utilized to enhance the apoptosis resistance of the mesenchymal stem cells and promote the homing of the mesenchymal stem cells, thereby providing a new technical scheme for preparing drugs for treating cardiovascular diseases in clinic. The prepared allogenic mesenchymal stem cells can not cause immunological rejection after cell transplantation.

The invention discloses a moderate skin cream containing multiple kinds of pure natural plant extracts. A pure natural green tea extract, a liquorice root extract, a rosmarinus officinalis leaf extract, a scutellaria baicalensis root extract, a chrysanthemum extract and a centella asiatica extract are added in raw materials of the skin cream, and all have effects of resisting inflammation and adjusting immunity; the skin cream is capable of completely inhibiting a dozen of inflammatory factors, rapidly stopping skin inflammations caused by various reasons and inhibiting malignant linkage physiological reactions in all stages of the inflammations, has an effect of sephalosprins and is safe without side effects, also has cooperative effects of resisting oxidization, soothing and preserving moisture, and especially has a remarkable clinical effect for nursing of sensitive skin and skin of infants; and the six kinds of selected pure natural plant extracts are added in the skin cream, so that the symptoms such as inflammation and allergies caused by factors such as climate, environment and stimulating substances of the infants can be greatly reduced, the tender and lovely skin of the infants is protected, and thus the moderate skin cream is suitable for being used by the infants.

The invention relates to a 8-pyrazole substituted xanthine A2B adenosine receptor antagonist and a synthesis method and an application thereof. The structural formula of the A2B adenosine receptor antagonist is shown in the specifications, and the antagonist is synthesized by taking 1,3-dialkyl-5,6-diaminouracil and nitrobenzyl pyrazole-4-formic acid as raw materials and improving a Traube reaction. The synthesis method disclosed by the invention has mild conditions, low cost and high yield, is easy to operate, and is suitable for industrial production. As proved by a pharmacological experiment, the affinity and selectivity of an A2B receptor are enhanced due to substitution of the 8-position of xanthine in 8-pyrazole substituted xanthine with nitrobenzyl pyrazole, the secretion of IL-8 can be suppressed, and the release of inflammatory factors is reduced. The receptor antagonist is suitable for treating bronchial asthma.

The invention relates to the molecular biology field and particularly relates to a gene knockout carrier, a construction method and application thereof and a gene knockout method of an NLRP1 gene of an MH7A cell. A CRISPR-Cas9 gene knockout system is utilized for carrying out CRISPR targeting sequence design by taking NLRP1 as a target gene so as to prepare a knockout carrier aiming at the NLRP1 gene, and the knockout carrier is utilized for transfecting the MH7A cell, so that the NLRP1 gene in the MH7A cell can be efficiently knocked out; and therefore, a research platform for rheumatoid arthritis is effectively built, so that the research of the pathogenesis of the rheumatoid arthritis is greatly promoted, and the researches of the interaction of NLRP1 inflammasomes and various inflammatory factors and the disease related molecular mechanisms of the rheumatoid arthritis and meningitis can be promoted.

The invention discloses a protein chip kit for detecting inflammatory factors, which comprises a basement membrane (1) and a reactant and a detection agent (2). A plurality of kinds of specific antibodies are fixed on the basement membrane; the specific antibodies and the inflammatory factors can undergo an antigen-antibody reaction and each specific antibody is respectively fixed on the basementmembrane for forming a plurality of independent recognition loci; and the reactant and the detection agent are used for detecting whether substances capable of undergoing the antigen-antibody reaction with the specific antibodies exist in a sample to be detected or not by an array-ELISA method. The invention also discloses a method for preparing the protein chip kit for detecting the inflammatoryfactors, which comprises a step of fixing the specific antibodies on the basement membrane. The kit of the invention adopts protein chip technology, can detect 40 inflammatory factors, overcomes a plurality of shortcomings and has the advantages of low cost, convenient use, high sensitivity and accuracy, high flux, small using amount of samples, capability of being popularized in an ordinary laboratory, massive production and the like.

Described is use of Salvia hispanica L. (Chia) for controlling, in one embodiment reducing, blood glucose levels, preferably post-prandial blood glucose levels. This is useful in both non-diabetic and diabetic individuals, but especially in diabetic individuals. Also described is the use of chia in reducing postprandial blood glucose, insulin sensitivity, blood pressure, and oxidative stress in such individuals. The present invention further found that Chia can be used to improve endothelial function, coagulation, fibrinolysis and iron status. The present invention further encompasses the use of Chia in the treatment and / or management of diabetes and / or the treatment and management of diabetes associated conditions or risk factors, such as one or more of the following: blood pressure and blood glucose levels, post-prandial glycemia, inflammatory factors (C-reactive protein), coagulation (fibrinogen, factor VIII, von Willenbrand factor), and fibronolytic factors (such as t-PA), iron status and endothelial function, (such as increase in nitric oxide generation). In one embodiment the invention relates to dietary approaches to such treatment and management.

The invention belongs to the field of traditional Chinese medicine pharmacy, and relates to the novel medical usage of icaritin, in particular to the usage of icaritin in preparation of medicine for preventing and treating endotoxemia. Lipopolysaccharide (LPS) is used for stimulating the macrophage system RAW264.7 of a mouse and establishing an extraneous endotoxic inflammation model, LPS is used for stimulating the C57BL / 6J mouse and establishing the endotoxemia animal model, icaritin is adopted for intervention, and dexamethasone is used as reference. The experiment result shows that the icaritin can reduce the death rate, the level of the inflammatory factor, the inflammatory mediator and the adhesion molecules and infiltration of inflammatory cells of the tissue after the mouse is attacked by endotoxin, and proves that the icaritin can effectively prevent and treat endotoxemia and can be used for further preparing effective drug for preventing and treating endotoxemia, including dosage forms such as oral and enteric capsules or intravenous injections.

The invention discloses a compound as a formula (1), a kalium salt, a sodium salt or an ammonium salt thereof and also discloses a pharmaceutical composition containing the compound as the formula (1), an isoandrographolidume sulfonate E, an andrographolic acid and andrographolidume and a preparation method thereof. The compound and the composition obtained by the method have favorable effects, such as an inflammatory factor resistant effect, an antibacterial effect, an analgesic effect and an antineoplastic effect. The invention also discloses a peroral preparation or an injection preparation prepared by using the compound and the composition.

Provided is an auto-immune disease-related microRNA. In particular, provided is the miR-23b generally down-regulated in the partially inflamed tissue, and further provided are members of the miR-23 family capable of inhibiting the occurrence and development of auto-immune disease after the members are introduced, comprising miR-23a, miR-23b and miR-23C. Also provided is the use of the microRNA in the treatment and prevention of auto-immune disease. The expression of miR-23b is regulated by IL-17, and targets the genes of TAB2 and TAB3, etc., in the signal pathway of inflammatory factors; by inhibiting the expression of TAB2 and TAB3, miR-23b can inhibit the occurrence and development of auto-immune disease and significantly relieve the symptoms and development of the disease.

The present invention provides a more safe and highly effective stent having functions such as anti-inflammatory action, antithrombotic action, maintenance of tissue restoration response and maintenance of endothelial regeneration. More specifically, the drug / gene eluting stent has a layer containing a gene encoding a hybrid polypeptide on the surface. The hybrid polypeptide is preferably a bound of fibronectin-derived collagen binding domain (FNCBD) polypeptide and an anti-inflammatory factor or an angiogenic factor. The uniform fine particle size capsules can directly deliver the gene encoding the hybrid polypeptide to the lesion and have benefits of reducing the given doses, and thus improving safety and efficacy and further maintaining the efficacy for a long period.

The invention belongs to the field of pharmaceutical chemistry, and specifically relates to an application of specific chalcone compounds in the preparations of inflammation resisting medicines and medicines used for treating inflammation-related diseases. With the chalcone compounds, expression and release of various inflammatory factors such as TNF-alpha, IL-6, COX-2, IL-1beta and IL-12 can be inhibited; nuclear translocation of an inflammation-regulation-related nuclear factor -kappaB can be substantially inhibited; and phosphorylation of inflammation signal pathways ERK and p38 can be inhibited. As a result of in-vivo experiments, with the compounds, the survival rate of LPS-introduced mice mortality can be substantially improved.

The invention provides a styrene system ion exchange resin as well as a preparation method and application thereof. The styrene system ion exchange resin is prepared by taking styrene and toluylene as monomers and is a milk-white nontransparent spherical particle; the diameter is 0.05-1.20 mm; the density is as follows: the true wet density is 1.06-1.10 g / ml, and the apparent wet density is 0.65-0.75 g / ml; the strength (attrited sphericity) is more than or equal to 95%; the surface active group is -N+(CH3)2; the aperture is 80-100 nanometers; the porosity is 45%-22%; the pore volume is 0.75-0.84 ml / g; the specific area is 850-1000 m<2> / g; the full exchange capacity of dry resin is 3.7 mmol / g, and the full exchange capacity of wet resin is 1.1 mmol / g. The styrene system ion exchange resin provided by the invention is an effective cell factor adsorbing material, achieves outstanding adsorption effect on endotoxins and inflammatory factors which are contained in blood and can be applied to the aspect of resin hemoperfusion apparatus.

The invention relates to a novel function and application of seville orange flower extract. Particularly, hesperidin, neohesperidin and other flavonoid substances in the seville orange flower extract are capable of promoting cell proliferation and expression of mRNA of fibrocyte IV-type collagen, inhibiting activities of elastase and matrix metalloproteinase, reducing damage of ultraviolet ray to cells and reducing the level of reactive oxygen species and secretion of inflammatory factors, so that the seville orange flower extract has a function of resisting radiation and aging for skins. Therefore, the invention provides a new direction of seville orange flower extract application, namely application of the seville orange flower extract in skin protecting products.

The invention relates to a whitening composition (uniGlow) and an application thereof. The whitening composite comprises phenylbenzimidazole sulfonic acid, hydroxyphenylpropylamide benzoic acid, dipotassium glycyrrhizinate, undecylenoyl phenylalanine, hydrolyzed shellfish protein, beta-arbutin, ellagic acid, sodium ascorbate phosphate, carnosine, nicotinamide, inositol, papain and hesperidin extract. The whitening composition performs targeted inhibition from the melanin forming inducements of UV, inflammatory factors, melanoma and endothelin; in the melanin synthesis process, tyrosinase inhibits the reduction with a melanin intermediate, blocks the melanin transfer pathway, accelerates stratum corneum spalling and accelerates the metabolism; by conditioning, the skin is fine, tight, natural, white and bright.

The invention relates to the field of biological medicines, in particular to application of an erythropoietin source peptide to the preparation of a medicament for treating an autoimmune disease of a nervous system. When the erythropoietin source peptide and an erythropoietin source peptide liposome are used for treating the autoimmune disease of the nervous system, the autoimmune diseases athletic ability of the nervous system of a rat is recovered, the limb reflecting capability is remarkably improved, and the activating quantity of macrophages and the expression quantity of inflammatory factors are remarkably suppressed; more importantly, the function of the erythropoietin source peptide liposome is better than that of the erythropoietin source peptide, and the administration frequencyis reduced remarkably; and when the erythropoietin source peptide and the erythropoietin source peptide liposome are used, the hematopoietic function is not induced.

The invention discloses an L.plantarum UA149 strain and an application thereof, and belongs to the field of functional food microorganisms. The L.plantarum UA149 strain is deposited in China Typical Culture Collection Center on November 29, 2018 with the preservation number of CCTCC No: M2018842. The strain can be apply to preparing products with a uric acid reducing function or a gout resisting function. Lactic acid bacteria separated and identified from the surface of fleshy plant leaves are taken as research objects, and a new strain of lactic acid bacteria is screened through a large number of experiments. Hyperuricemia model rats are established by potassium oxazinate combined with fructose water, continuous intragastric administration of the lactobacillus plantarum UA149 strain for 14 days can significantly reduce the level of uric acid; and during gout attack, the release of inflammatory factors thromboxane and leukotriene mediated by neutrophils is reduced, the influx of neutrophils into joints is avoided, and the symptoms of redness, swelling, pain, heat and the like are reduced.

The invention discloses application of a phyllanthus emblica extract in preparation of health food or cosmetics with anti-radiation, anti-inflammation and anti-aging efficacy, the phyllanthus emblica extract has anti-UVA (Ultra Violet A) radiation efficacy, can substantially reduce cell damage caused by UV radiation, simultaneously has an obvious inhibition effect on macrophage inflammatory factor expression, and can play anti-inflammation and anti-aging effects; the invention also illuminates, in cell and molecular level, that the phyllanthus emblica extract has anti-UV radiation and anti-aging effects. In addition, the invention also discloses a preferred preparation method of the phyllanthus emblica extract having the anti-radiation and anti-aging effects.

The invention provides an application of lactobacillus rhamnosus in regulating immunity. The lactobacillus rhamnosus is preserved in China General Microbiological Culture Collection Center on August 10, 2017, has the preservation number of CGMCC No.14511, and is classified and named as lactobacillus rhamnosus. The lactobacillus rhamnosus has good immunoregulatory effect on a body, has the inhibiting effect on the expression of inflammatory factors, the promotion effect on the anti-inflammatory factors and the promotion effect on lymphocyte proliferation significantly better than those of conventional commercial lactobacillus rhamnosus strains, and has immunoregulatory function on the body significantly better than that of the conventional lactobacillus rhamnosus strains.

The invention provides ganoderma lucidum compounds and a medicine composition thereof, as well as a preparation method and an application of the compounds. Four pairs of optical enantiomers are separated and identified from ganoderma lucidum, wherein two pairs are new compounds which are named as L-ganoderma lucidum or R-ganoderma lucidum E and F respectively. The new compounds show an application prospect in preparation of medicines and foods resisting diabetic nephropathy or chronic nephrosis because of being capable of remarkably inhibiting kidney mesangial cells induced by high glucose from generating inflammatory factors or extracellular matrixes.

The invention relates to an application of anthropogenic lactobacillus casei grx12 in the aspect of chronic alcoholic liver injury. The lactobacillus casei grx12 is a probiotic strain with an obvious in-vitro antioxidant capacity, which is obtained in a separation mode from the intestinal tracts of people in the long life village of Rugao city, Jiangsu province. The lactobacillus casei grx12 is preserved in China General Microbiological Culture Collection Center (CGMCC) of China Committee for Culture Collection of Microorganisms (CCCCM) and has the preservation number of CGMCC No.7696. The lactobacillus casei grx12 can be used for obviously decreasing the level of toxins in blood fat and blood serum of a rat with the alcoholic liver injury, decreasing the expression of liver inflammatory factors in the liver and relieving the inflammatory reaction of the liver, thereby having obvious protection functions to the chronic alcoholic liver injury.

The invention discloses a preparation method of a herba portulacae extracting solution. The preparation method comprises steps as follows: fresh herba portulacae is weighed and crushed into herba portulacae pulp by a crusher; ethanol with the volume percentage being 50%-75% is added, the mixture is stirred at the temperature of 60-80 DEG C, extracted for 1-3 h and filtered, filtrate I is obtained and then distilled, ethanol is recovered, water is added until the volume of original filtrate I is reached, and filtrate II is obtained; an activated carbon and activated clay compounded decolorizing agent is added to the filtrate II, the filtrate II is decolorized for 20-40 min at the temperature of 20-80 DEG C, and activated carbon is filtered out with a ceramic membrane; filtrate with the molecular weight smaller than 150-300 is intercepted with a nanofiltration membrane, and filtrate III is obtained; a humectant is added to the filtrate III, then, a preservative is added, and the herba portulacae extracting solution is obtained. The preparation process of the herba portulacae extracting solution is simple to operate, and industrial production is facilitated; the herba portulacae extracting solution prepared with the preparation method has high anti-UVA (ultraviolet A), free radical scavenging and in-vitro oxidation resistance characteristics and cannot cause inflammatory factors.

The invention discloses a bi-target CAR-T cell. The bi-target CAR-T cell is characterized in that two target antigens which are in co-expression in tumor cells and are not in co-expression in normal cells are utilized, an antibody variable region of one target antigen is fused with a killing signal in a T cell, and an antibody variable region of the other target antigen is fused with a co-stimulating signal in the T cell, and two different expression cassettes are formed, so that the bi-target CAR-T cell is constructed; the constructed bi-target CAR-T cell can just identify tumor cells which can express the two target antigens at the same time and cannot identify the normal cells which just express one target antigen. The invention also discloses a preparation method and application of thebi-target CAR-T cell. According to the bi-target CAR-T cell disclosed by the invention, not only killing specificity is increased, but also killing of the normal cells is reduced, and side effects brought by an inflammatory factor storm are reduced.

The invention discloses a composition for repairing sensitive skin. The composition contains ceramide, glycosylglycerol, stearic acid, oleic acid, cholesterin, sodium hyaluronate, bio-saccharide gum-1, barley extract, glycerin, glucan, butylene glycol, pentanediol, hydrogenated lecithin and pure water. According to the invention, the problem of sensitivity of the skin is overcome through the co-action of external and internal factors, so sensitive skin can be comprehensively repaired, external repairing of the barrier function of the stratum corneum is realized, the possibility of entering ofsensitive components into the human body is lowered, internal inhibition of inflammatory factors is achieved, and the occurrence of allergy is alleviated; meanwhile, the composition replenishes and retains moisture, reduces the incidence of dryness and sensitivity of the skin, increases the number of fibroblasts, also has good effect on skin repairing, can overally reduce the incidence of allergies and makes the skin more and more healthy.

The invention belongs to the field of applications of biomedical materials and specifically relates to a preparation method of a collagen-based sponge wound dressing with a self-anti-inflammatory function. The dressing is of a sponge type, is soft in texture, has a uniform porous structure, and can be used for fast absorbing water for swelling, effectively reducing the secretion of inflammatory factors, eliminating inflammation of a wound, absorbing secretions of the wound and promoting the repair of the wound; and simultaneously, the sponge is resistant to enzymatic degradation, can be used for reducing the number of times of replacement and can be applied to repair of a variety of skin wounds, such as burns and mechanical injuries. The preparation method comprises the following steps: performing partial ring opening on polyvinylpyrrolidone in a potassium hydroxide solution at high temperature and high pressure, further mixing the polyvinylpyrrolidone after ring opening with collagen to prepare a solution, taking 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide as activators for cross-linking, then performing deionized water soaking and washing on a cross-linked product, removing the surplus activators, and then freeze-drying for getting the dressing.

The invention belongs to the technical field of daily cosmetics, and discloses an anti-oxidation, anti-glycation and anti-aging skin care composition and an application thereof. The composition mainlycomprises carnosine, ultra-low molecular weight dendrobium officinale polysaccharide extract and bifida ferment lysate, and also can comprise a solvent and a preservative. By golden proportioning andcombined use of three components including the carnosine, the ultra-low molecular weight dendrobium officinale polysaccharide extract and the bifida ferment lysate, the synergistic effect is achieved, so that the composition has the effects of resisting oxidation, resisting glycosylation, inhibiting release of inflammatory factors by human keratinocytes after photodamage, promoting expression ofbarrier repair genes and promoting synthesis of collagen, and takes the comprehensive anti-ageing effect. In addition, the anti-oxidation, anti-glycation and anti-aging skin care composition is simplein component type and easy to prepare and easy to mix with other components in the cosmetics, and has the obvious advantage of being easy to add in various types of formulas.

The invention discloses a lactobacillus reuteri 22 and application thereof. The lactobacillus reuteri 22 disclosed by the invention is separated from healthy chicken flocks, is classified and named aslactobacillus reuteri, and has a preservation number of CGMCC No.17932. By detecting the performance of probiotics, the invention finds that the lactobacillus reuteri 22 has good acid resistance, cholate resistance and adhesion performance, and can inhibit growth of pathogenic bacteria. Through Animal assays, in a healthy physiological state, the lactobacillus reuteri 22 does not influence the level of inflammatory factors, but can increase the number of goblet cells and promote the increase of expression levels of related genes such as compact protein, defensin and lysozyme, can increase thelength of intestinal villi and the depth of crypt, and has the potential of maintaining intestinal mucosa barriers. Therefore, the strain is expected to be developed into probiotics for maintaining achicken intestinal mucosa barrier and guaranteeing green and healthy chicken breeding.

The invention relates to an adsorbent for removing inflammatory factors in blood of a patient with inflammatory reaction on the whole body through blood or plasma perfusion and a preparation method thereof. The adsorbent is a nano composite structure adsorbent, is a cell factor adsorbent prepared by using nano calcium carbonate-styrene-divinylbenzene as a basic framework, using toluene, gasoline and a multi-carbon alcohol mixture as pore-foaming agents and using benzoyl peroxide as an initiator and has a developed mesoporous structure and high specific surface area. By introducing the nano material, the efficiency of removing the inflammatory factors in blood or blood plasma of the adsorbent is greatly improved. The adsorbent is simple to prepare, has the efficient removal effect on inflammation factors such as IL-6, TNF-alpha, IL-beta 1 and IL-8 and is used for removing the excessive pathogenic inflammatory factors in the patient body in a blood or blood plasma perfusion mode.

The invention relates to a compound with effects of resisting inflammation and platelet activation and aggregation as well as a preparation method and application thereof. The compound has the structure of (25R)-26-oxy-beta-D-glucopyranose-5alpha-furostanol-3beta,12beta,22,26-tetraalcohol-3-oxy-beta-D-glucopyranose(1->2)[beta-D-glucopyranose(1->3)]-beta-D-glucopyranose(1->4)-beta-D-galapyranoside. The effects of the compound in the field of cardial vessels are comprehensively researched from platelet aggregation, platelet activation, platelet calcium ion variation, platelet activation signal transduction pathway and expression of platelet activation relevant inflammatory factors in the invention for the first time. Results show that the compound is a substance found to be with a strong effect on resisting platelet aggregation so far in the allium macrostemon saponin compounds, which has the stronger effect than that of aspirin with the same concentration; and the compound simultaneously has an obvious effect on resisting relevant platelet inflammations. The compound provided by the invention can be applied to medicines for treating thrombus and atherosclerosis.